Provenge Data Not Supportive Of Off-Label Uses, MEDCAC Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
The existing clinical data on Dendreon's prostate cancer vaccine Provenge cannot be "generalizable" to off label uses, most members of the Medicare Evidence Development and Coverage Advisory Committee agreed at a Nov. 17 meeting.